Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. GOOGL
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
CYTOKINETICS (NASDAQ: CYTK) Delayed: 79.17 +0.39 (0.50%)
Previous Close $78.78    52 Week High $13.18 
Open $80.00    52 Week Low $6.00 
Day High $80.80    P/E N/A 
Day Low $78.36    EPS $-1.24 
Volume 2,888,293       

REPROS THERAPEUTICS (NASDAQ: RPRX) Delayed: 53.57 +0.61 (1.15%)
Previous Close $52.96    52 Week High $3.48 
Open $53.27    52 Week Low $0.80 
Day High $53.71    P/E N/A 
Day Low $52.89    EPS $-1.54 
Volume 4,091,975